Greenhaven Road Capital Highlights Burford Capital’s Potential

In its second-quarter 2026 investor letter, Greenhaven Road Capital, an investment management company, highlighted Burford Capital Limited (NYSE:BUR) as a leading legal finance company that offers litigation finance, asset recovery, and asset management services. The fund, which achieved an approximate 11% net return in the second quarter, has taken a proactive stance on profit-taking and will focus on owning strong businesses while conducting research that challenges consensus views.

According to the letter, Burford Capital Limited (NYSE:BUR) is the 800-pound gorilla of litigation finance, with the best settlement data and an advantage in selecting and funding cases profitably. The company has invested more than $150M in price-fixing cases involving proteins, including chicken, beef, turkey, and pork. For much of this capital, Burford retains all of the upside rather than sharing it with a client, and it controls when the cases settle.

Burford’s settlements could exceed the company’s market capitalization and could arrive within the next year as these matters begin going to trial. The defendants in these cases are very large companies, including Tyson Foods (TSN), Pilgrim’s Pride (PPC), Koch Foods, and Cargill. Combined, they have already spent billions settling some of these antitrust claims. If they lose at trial, they face treble damages, giving all parties an incentive to settle.

Greenhaven Road Capital emphasized that Burford Capital Limited (NYSE:BUR) has a strong track record of success, with more than 285 funded cases concluded, and 90% of them ending in a win or profitable settlement. These investments produced an 82% return on invested capital over a weighted average life of 2.6 years, resulting in a 25% IRR.

Burford Capital’s Protein Cases: A Potential Game-Changer

The protein cases are a significant catalyst for Burford Capital Limited (NYSE:BUR), with the potential for massive returns. The company’s settlements could exceed its market capitalization and arrive within the next year. This is a promising opportunity for investors looking to capitalize on Burford’s expertise in litigation finance.

Greenhaven Road Capital’s focus on owning strong businesses and conducting research that challenges consensus views is a key aspect of its investment strategy. By highlighting Burford Capital Limited (NYSE:BUR) in its second-quarter 2026 investor letter, the fund is emphasizing the potential for significant returns in the protein cases.

Key Statistics and Figures

Burford Capital Limited (NYSE:BUR) has invested more than $150M in price-fixing cases involving proteins.

The company has a strong track record of success, with more than 285 funded cases concluded, and 90% of them ending in a win or profitable settlement.

These investments produced an 82% return on invested capital over a weighted average life of 2.6 years, resulting in a 25% IRR.

Burford’s settlements could exceed its market capitalization and arrive within the next year.

The defendants in these cases are very large companies, including Tyson Foods (TSN), Pilgrim’s Pride (PPC), Koch Foods, and Cargill.